These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34278551)

  • 21. Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan.
    Takaya R; Mori N; Saito E; Ohde S
    BMC Health Serv Res; 2024 Mar; 24(1):389. PubMed ID: 38549158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
    Martin-Loeches I; Bisanti A; Diaz E; Rodriguez A
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1177-1185. PubMed ID: 32662691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant
    Gallagher JC; Satlin MJ; Elabor A; Saraiya N; McCreary EK; Molnar E; El-Beyrouty C; Jones BM; Dixit D; Heil EL; Claeys KC; Hiles J; Vyas NM; Bland CM; Suh J; Biason K; McCoy D; King MA; Richards L; Harrington N; Guo Y; Chaudhry S; Lu X; Yu D
    Open Forum Infect Dis; 2018 Nov; 5(11):ofy280. PubMed ID: 30488041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
    Carvalhaes CG; Castanheira M; Sader HS; Flamm RK; Shortridge D
    Diagn Microbiol Infect Dis; 2019 May; 94(1):93-102. PubMed ID: 30642717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
    Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel GG; Dhami R; Baxter M; Kosar J; Cervera C; Irfan N; Zvonar R; Borgia S; Tessier JF; Dow G; Ariano R; Dube M; Savoie M; Bassetti M; Walkty A; Karlowsky JA
    J Glob Antimicrob Resist; 2021 Jun; 25():346-350. PubMed ID: 33984530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam.
    Van Anglen LJ; Schroeder CP; Couch KA
    Open Forum Infect Dis; 2023 May; 10(5):ofad173. PubMed ID: 37180591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
    Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
    Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftolozane-tazobactam for the treatment of multidrug-resistant
    Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
    Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of
    Belkhair J; Nachat S; Rouhi S; Ouassif H; Abbassi S; Soraa N
    New Microbes New Infect; 2021 May; 41():100872. PubMed ID: 33912351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.
    Motos A; Li Bassi G; Pagliara F; Fernandez-Barat L; Yang H; Aguilera Xiol E; Senussi T; Idone FA; Travierso C; Chiurazzi C; Amaro R; Yang M; Bobi J; Rigol M; Nicolau DP; Frigola G; Cabrera R; Ramirez J; Pelosi P; Blasi F; Antonelli M; Artigas A; Vila J; Kollef M; Torres A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.
    Fiore M; Corrente A; Pace MC; Alfieri A; Simeon V; Ippolito M; Giarratano A; Cortegiani A
    Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33467508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials.
    Rotstein C; Lynch JP; Zhanel GG
    Expert Rev Anti Infect Ther; 2023 Oct; ():1-13. PubMed ID: 37811572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated
    Kunz Coyne AJ; Orzol C; Veve MP; Rybak MJ
    Open Forum Infect Dis; 2023 Sep; 10(9):ofad454. PubMed ID: 37720698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.